Ipamorelin

Ipamorelin is a lab-made peptide (a short chain of amino acids, the building blocks of proteins) that briefly nudges up your body’s growth hormone (GH). It has been tested in people, but the one trial that checked for a real-world health benefit didn’t pan out, and it has never been approved for any use.

What it is

Ipamorelin is a pentapeptide, meaning it’s built from five amino acids (its sequence is Aib-His-D-2-Nal-D-Phe-Lys-NH2). The drugmaker Novo Nordisk created it and gave it the code name NNC 26-0161.

It works by latching onto a specific docking point on your cells called the ghrelin / growth-hormone-secretagogue receptor (GHS-R1a) — the same one your natural hunger-and-growth hormone, ghrelin, uses. Flipping that switch tells the pituitary gland (a small hormone gland at the base of the brain) to release a burst of growth hormone.

Its main bragging point in the research is that it’s “selective” — meaning it does one thing without dragging others along. In studies it raised GH without meaningfully bumping up other hormones like ACTH, cortisol (your main stress hormone), or prolactin. That sets it apart from some older GH-releasing peptides, which were less tidy.

The claims

Sellers and wellness clinics pitch ipamorelin — often paired with another peptide called CJC-1295 — for building muscle, losing fat, recovering faster, sleeping better, slowing aging, and giving a “natural” growth-hormone boost. The pitch goes like this: a gentle, on-and-off GH bump should hand you the perks of growth hormone without the downsides of injecting GH straight into your body.

What the evidence actually shows

Human data do exist, but there isn’t much, and what’s there isn’t encouraging for those claims.

A Phase 1 study (an early, small human safety trial) in 40 healthy men (Gobburu et al., 1999) showed ipamorelin acts the way a small peptide should: the bigger the dose, the bigger the response; it clears from the body with a roughly 2-hour half-life (the time it takes for half the drug to leave your system); and it causes a sharp GH spike that peaks in under an hour and fades within about six hours. In short, it does its biochemical job.

But the real test is whether any of that actually changes a person’s health. The most rigorous human trial was a randomized, double-blind, placebo-controlled Phase 2 study (NCT00672074) — the gold-standard setup, where neither patients nor doctors know who got the real drug, and it’s compared against a dummy treatment. It looked at ipamorelin given by IV (into a vein) for postoperative ileus (when the gut temporarily stops moving things along after surgery) in roughly 114 patients recovering from bowel-resection surgery. Ipamorelin lost to the placebo: it didn’t meaningfully speed up the return of normal bowel function or get patients to their first tolerated meal any sooner (about 25 hours versus 33 hours on placebo — a gap small enough that it could easily be chance). Development was then dropped for lack of efficacy (because it didn’t work well enough).

There are no published long-term human trials backing the muscle, fat-loss, recovery, sleep, or anti-aging claims — that evidence is basically missing. So the honest takeaway is: we know what it does to GH in the short term, but the one trial that measured a real outcome came up empty, and the popular benefits remain unproven.

Legal and regulatory status

Ipamorelin is not FDA-approved for anything, and never has been. Its standing for use in compounding (when a pharmacy custom-mixes a medication) has been tight.

In September 2023 the FDA placed ipamorelin acetate in Category 2 of its interim 503A bulk-substances list — the bucket for ingredients the agency thinks may carry significant safety risks. It was taken off that list in September 2024 after the request to include it was withdrawn, and the FDA’s Pharmacy Compounding Advisory Committee then voted against adding ipamorelin to the 503A bulks list at its late-2024 meetings. The bottom line, as of mid-2026: there’s no clear, legal way for compounding pharmacies to use it. Instead it’s sold mostly as a “research chemical” — a label that tells you nothing about whether it’s pure or safe.

In sports, the World Anti-Doping Agency bans ipamorelin at all times as a growth-hormone secretagogue (category S2). And because it has no approved medical use, there’s essentially no legitimate way to get a therapeutic use exemption (special permission to use a banned substance for a genuine medical reason).

Safety

There’s no meaningful long-term safety data in humans. The trials that exist were short, so we know very little about taking it repeatedly or over a long stretch.

The general worries for this whole class of drugs include keeping GH and IGF-1 (a growth-related hormone GH triggers) elevated, effects on blood sugar and insulin sensitivity (how well your body responds to insulin), and water retention. Purity is a real-world concern too: anything sold outside approved channels isn’t regulated and could contain impurities. None of this is medical advice.

Bottom line

Ipamorelin reliably gives a short GH burst in people, but its one solid trial of whether it actually helps failed, the popular benefits are unproven, it’s unapproved with no legal compounding route, and it’s banned in sport.

Evidence grade: 6/10 · Preliminary.

Sources

• Gobburu JV, Agersø H, Jusko WJ, Ynddal L. Pharmacokinetic-pharmacodynamic modeling of ipamorelin, a growth hormone releasing peptide, in human volunteers. Pharm Res. 1999;16(9):1412-1416.
• Beck DE, Sweeney WB, McCarter MD. Prospective, randomized, controlled, proof-of-concept study of the ghrelin mimetic ipamorelin for the management of postoperative ileus in bowel resection patients. Int J Colorectal Dis. 2014;29(12):1527-1534.
• ClinicalTrials.gov NCT00672074 — Ipamorelin for postoperative ileus (Phase 2)
• FDA — Certain Bulk Drug Substances for Use in Compounding That May Present Significant Safety Risks (interim 503A Category 2)
• World Anti-Doping Agency — The Prohibited List (S2: Peptide Hormones, Growth Factors, Related Substances and Mimetics)
• Ipamorelin — Wikipedia (structure, development history, selectivity)